Travere Therapeutics (NasdaqGM:TVTX) announced a planned CEO and President transition effective December 1, 2026. Dr. Eric ...
Travere Therapeutics has delivered a very large share price gain over the past few years, which naturally puts the focus on ...
Travere Therapeutics teilte am Mittwoch mit, dass das Unternehmen vom US-Patent- und Markenamt eine Mitteilung über die ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled ...
Eric Dube, Ph.D., the CEO who rebranded Travere Therapeutics and oversaw the launch of its rare kidney disease drug Filspari, will ...
Travere Therapeutics, Inc. und Eric Dube, Ph.D., haben am 21. September 2026 im gegenseitigen Einvernehmen den Zeitplan und ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Avviso esplicito sui rischi: Il trading degli strumenti finanziari e/o di criptovalute comporta alti rischi, compreso quello ...
Travere Therapeutics has announced that Bradley L. Campbell will become President and Chief Executive Officer on December 1, 2026, succeeding Eric Dube, Ph.D., who has decided to step down after ...
Le 21 septembre 2026, Travere Therapeutics, Inc. et Eric Dube, Ph.D., ont convenu d'un commun accord du calendrier et des modalités de la transition prévue du Dr Dube. Ce dernier quittera ...
Travere Therapeutics named Bradley Campbell as president and chief executive officer, effective Dec. 1. Campbell's appointment comes as the biopharmaceutical company's president and CEO Eric Dube ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results